Jan Sahai, PharmD; Keith Gallicano, PhD; Lori Swick, BSc; Sandra Tailor, PharmD; Gary Garber, MD; Isabelle Seguin, RN; Linda Oliveras, MLT; Scott Walker, MSc; Anita Rachlis, MD; D. William Cameron, MD
Reports suggest that antituberculosis drugs are malabsorbed in patients with advanced HIV disease.
To evaluate the pharmacokinetics of antituberculosis agents in HIV-seropositive patients at different stages of disease.
Two hospital outpatient clinics.
12 healthy volunteers, 12 patients with asymptomatic HIV disease, 12 patients with symptomatic HIV disease, and 12 patients with symptomatic HIV disease and diarrhea.
Drug plasma concentrations were measured over 24 hours on day 4 of concurrent therapy.
Oral isoniazid (300 mg/d), rifampin (600 mg/d), pyrazinamide (1000 mg/d), and ethambutol (1000 mg/d).
Reduced total drug exposure to rifampin and pyrazinamide was associated with D-xylose malabsorption in persons with HIV infection or AIDS. Peak drug exposure to isoniazid was lower in patients with diarrhea.
Reduced total drug exposure may be related to malabsorption in persons with HIV infection or AIDS.
Sahai J, Gallicano K, Swick L, et al. Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection. Ann Intern Med. 1997;127:289–293. doi: https://doi.org/10.7326/0003-4819-127-4-199708150-00006
Download citation file:
Published: Ann Intern Med. 1997;127(4):289-293.
HIV, Infectious Disease, Mycobacterial Infections.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use